Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

AIMS/OBJECTIVES: In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and β(3)‐adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Clin Pract
Auteurs principaux: Drake, Marcus J., MacDiarmid, Scott, Chapple, Christopher R., Esen, Adil, Athanasiou, Stavros, Cambronero Santos, Javier, Mitcheson, David, Herschorn, Sender, Siddiqui, Emad, Huang, Moses, Stoelzel, Matthias
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Urology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5485167/
https://ncbi.nlm.nih.gov/pubmed/28419650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12944
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires